Factocel VIII 250 IU Injection

Product Description

Factocel VIII 250 IU Injection is a vital treatment for individuals with hemophilia A, specifically designed to manage and prevent bleeding episodes in both adults and children. This antihemophilic factor, sourced from human plasma, plays a crucial role in restoring the deficient Factor VIII levels in patients, thereby promoting effective blood clotting. It is particularly beneficial during emergency situations and elective surgeries where the risk of bleeding is heightened. However, it is important to note that Factocel VIII is not suitable for treating von Willebrand disease, which involves a different clotting mechanism. Patients should be aware of potential side effects, and healthcare providers will monitor for any adverse reactions. As with any medical treatment, consulting with a healthcare professional is essential to ensure appropriate use and safety. By improving the quality of life for those affected by hemophilia A, Factocel VIII stands out as a critical therapeutic option in the field of hematology.